Andrew J. Aguirre

Nov 12, 2024 | nature.com | Alvaro Curiel-Garcia |Margo I Orlen |Clint A. Stalnecker |Julien Dilly |Marie C. Hasselluhn |Stephanie Chang | +16 more

Correction to: Nature https://doi.org/10.1038/s41586-024-07379-z Published online 8 April 2024In the version of the article initially published, in the Data availability section, the GEO accession number was incorrect and has now been amended to GSE252002 in the HTML and PDF version of the article.

Aug 18, 2024 | nature.com | Konstantine Tchourine |Keene L. Abbott |Florian Gourgue |Brian T. Do |Tenzin Kunchok |Allison Lau | +9 more

AbstractMetastases arise from subsets of cancer cells that disseminate from the primary tumour1,2. The ability of cancer cells to thrive in a new tissue site is influenced by genetic and epigenetic changes that are important for disease initiation and progression, but these factors alone do not predict if and where cancers metastasize3,4. Specific cancer types metastasize to consistent subsets of tissues, suggesting that primary tumour-associated factors influence where cancers can grow.

Apr 8, 2024 | nature.com | Grace Goodhart |Julien Dilly |Nicole Nasholm |Tamar Ziv |Jennifer Roth |Matthew Rees | +9 more

AbstractRAS oncogenes (collectively NRAS, HRAS and especially KRAS) are among the most frequently mutated genes in cancer, with common driver mutations occurring at codons 12, 13 and 611. Small molecule inhibitors of the KRAS(G12C) oncoprotein have demonstrated clinical efficacy in patients with multiple cancer types and have led to regulatory approvals for the treatment of non-small cell lung cancer2,3.

Apr 8, 2024 | nature.com | Alvaro Curiel-Garcia |Margo I Orlen |Clint A. Stalnecker |Julien Dilly |Marie C. Hasselluhn |Stephanie Chang | +16 more

AbstractBroad-spectrum RAS inhibition holds the potential to benefit roughly a quarter of human cancer patients whose tumors are driven by RAS mutations1,2. RMC-7977 is a highly selective inhibitor of the active GTP-bound forms of KRAS, HRAS, and NRAS, with affinity for both mutant and wild type (WT) variants (RAS(ON) multi-selective)3.

Dec 11, 2023 | nature.com | Carter Grochala |Jennifer L. Guerriero |Gerburg Wulf |Brian Wolpin |Ben Z. Stanger |Andrew J. Aguirre | +1 more

Retraction to: Nature Communications https://doi.org/10.1038/s41467-023-37096-6, published online 13 March 2023RETRACTION NOTEThe Editors retracted this article because of concerns regarding a number of figures presented in this work. These concerns call into question the integrity of the data and the article’s overall scientific soundness.